DMR-001 An investigational subcutaneous monoclonal antibody targeting mutant calreticulin in essential thrombocythemia and myelofibrosis, now in global Phase 1/1b testing.
Visit productCosigns Received
Be the first Cosign
Put your name behind DMR-001.
Add it to your Products I use list and share why you use it.